Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD) [0.03%]
Pembrolizumab联合立体定向体部放疗治疗索拉非尼治疗后晚期肝细胞癌的Ⅱ期临床研究(PEMRAD研究)
Grainne M O&#x;Kane,Aruz Mesci,Raymond W Jang et al.
Grainne M O&#x;Kane et al.
Background & aims: There is strong rationale for integrated approaches combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma (HCC). ...
STAT1 drives the immune landscape of murine Toll-like receptor 9-induced liver inflammation [0.03%]
STAT1驱动的TLR9诱导的小鼠肝脏炎症免疫微环境特征
Amber De Visscher,Jarne Beliën,Eline Bernaerts et al.
Amber De Visscher et al.
Background & aims: Persistent activation of Toll-like receptor 9 (TLR9) has been implicated in eliciting a cytokine storm syndrome, leading to systemic and hepatic inflammation in mice and humans. This study investigates ...
Single-cell analysis of heterogeneity in reverted hiPSC-derived human hepatic stellate cells [0.03%]
单细胞分析人类诱导多能干细胞源性肝星状细胞去分化异质性
Xinjia Wang,Eun Hee Ha,Lu Bian et al.
Xinjia Wang et al.
Background & aims: Activated HSCs are known to drive fibrogenesis, but their fate following injury resolution remains unclear. We aimed to investigate whether human activated HSCs revert to a less activated state, and to ...
Circulating HBV RNA and hepatitis B core-related antigen as determinants of HBsAg loss in persons with HIV in Europe [0.03%]
欧洲HIV感染者中HBV RNA和乙肝核心相关抗原与HBsAg消失的关系研究
Lorin Begré,Anders Boyd,Marie-Laure Plissonnier et al.
Lorin Begré et al.
Background & aims: HBsAg loss improves clinical outcomes in persons with HIV and HBV coinfection. We aimed to evaluate if hepatitis B core-related antigen and circulating HBV RNA levels were associated with HBsAg loss in ...
Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver disease [0.03%]
基于血液的维也纳3P/5P风险模型可准确预测代偿性晚期慢性肝病患者首次发生肝衰竭事件
Georg Kramer,Benedikt Simbrunner,Mathias Jachs et al.
Georg Kramer et al.
Background & aims: Invasive measurement of hepatic venous pressure gradient (HVPG) is the gold standard for diagnosing clinically significant portal hypertension (CSPH, i.e. HVPG ≥10 mmHg), which indicates an increased r...
Elexacaftor-tezacaftor-ivacaftor and cystic fibrosis liver disease: A turning point that calls for cautious optimism [0.03%]
艾勒萨法克托尔-特扎沙法克托尔-伊维沙法克托尔与囊性纤维化肝病：谨慎乐观的转折点
Pierre-Emmanuel Rautou,Sophie Hillaire,Simone Gambazza et al.
Pierre-Emmanuel Rautou et al.
Inhibition of estrogen receptor alpha stabilizes regulatory T cell function in autoimmune hepatitis [0.03%]
雌激素受体α抑制稳定自身免疫性肝炎调节性T细胞功能
Lina Zhang,Barbora Gromova,Du Hanh Nguyen et al.
Lina Zhang et al.
Background & aims: Regulatory T cell (Treg) dysfunction is a hallmark of autoimmune hepatitis (AIH), a serious hepatopathy often progressing to end-stage liver disease despite immunosuppression. Treg impairment in AIH has...
Integrating multiphase MRI surrogates to improve microvascular invasion detection and recurrence risk stratification in HCC [0.03%]
结合多阶段MRI替代标志物提高肝细胞癌微血管侵犯检测及复发风险分层的能力
Fan Li,Ruishan Liu,Jin-Ming Cao et al.
Fan Li et al.
Background & aims: Microvascular invasion (MVI) is a key determinant of recurrence and poor outcomes in hepatocellular carcinoma (HCC), yet accurate preoperative detection remains challenging. A deep-learning model integr...
Effects of hypothermic oxygenated machine perfusion on bile composition after liver transplantation - Findings from a randomized controlled trial [0.03%]
肝脏移植后模拟灌注对胆汁成分影响的随机对照试验发现
Frederik Schliephake,Isabella Lurje,Deniz Uluk et al.
Frederik Schliephake et al.
Background & aims: In liver transplantation, bile acid (BA) toxicity contributes to injury of both hepatocytes and cholangiocytes. While hypothermic oxygenated machine perfusion (HOPE) reduces ischemia-reperfusion injury ...
External beam radiation for HCC: Ready for incorporation into guidelines? [0.03%]
外部束放射治疗肝细胞癌：准备好写入指南了吗？
Michael Buckstein,Laura A Dawson
Michael Buckstein
External beam radiation therapy is becoming an increasingly useful tool in the management of hepatocellular carcinoma at all clinical stages. The data supporting its use is now maturing, with randomised trials showing excellent results in e...